Has Miyagi Henderson received payments from drug or device companies?

Yes. Drug and device makers reported $13,318 in general payments to Miyagi Henderson across 582 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Miyagi Henderson did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Miyagi Henderson come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Miyagi Henderson

Family · Slidell, LANPI 1588293518

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.5% of the total across 582 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,119, 7.4 times the $559 reported in 2021. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,318in general payments, 2019–2025

Across 582 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$3K
Sanofi$2K
Regeneron Healthcare Solutions, Inc.$1K
UCB, Inc.$1K
Johnson & Johnson$1K
LEO Pharma Inc.$906
plus $5K from 17 others

What the payments were for

Food & beverage$12,58995%
Education$7305%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	120	$2,519
Sanofi	80	$1,806
Regeneron Healthcare Solutions, Inc.	43	$1,361
UCB, Inc.	75	$1,123
Johnson & Johnson	33	$1,013
LEO Pharma Inc.	51	$906
Novartis	14	$812
E.r. Squibb & Sons, L.L.C.	24	$636
Pfizer	32	$628
Galderma Laboratories, L.p.	42	$562
Incyte Corporation	11	$471
Amgen	17	$426
Arcutis Biotherapeutics, Inc.	13	$316
Lilly USA, LLC	8	$226
Sanofi-aventis U.S. LLC	2	$168
Almirall LLC	3	$84
Sun Pharmaceutical Industries Inc.	3	$57
Mallinckrodt Hospital Products Inc.	2	$55
Medimetriks Pharmaceuticals, Inc.	3	$53
Paratek Pharmaceuticals, Inc.	2	$39
Hill Dermaceuticals, Inc.	1	$38
Verrica Pharmaceuticals Inc.	1	$14
Organon	2	$7

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DUPIXENT$1,394
Rinvoq$828
Skyrizi$559
OPZELURA$366
Sotyktu$346
EUCRISA$142
CIBINQO$142
COSENTYX$133
Humira$125
Otezla$125
ADBRY$125
Bimzelx$125
NEMLUVIO$125
Tremfya$121
ZORYVE$113

How this compares

$13,318 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana →

Medicare billing

Part B allowed, 2024

$56,504

Medicare patients

127

Services billed

892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	19	$274,385
Cosentyx Sensoready (2 Pens)Secukinumab	20	$152,517
Dupixent PenDupilumab	29	$128,878
OtezlaApremilast	12	$67,774
Dupixent SyringeDupilumab	15	$55,629
AdbryTralokinumab-Ldrm	12	$47,585
Clobetasol Propionate	70	$2,755
Tacrolimus	26	$2,071
Ketoconazole	68	$871
Doxycycline Monohydrate	33	$738
Triamcinolone Acetonide	47	$723
Betamethasone Dipropionate	11	$706
Betamethasone Valerate	15	$670
Clindamycin Phosphate	23	$664
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip	25	$565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AmgenOtezla	$426	$67,77412 claims
LEO Pharma Inc.Adbry	$906	$47,58512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.